HomeTWST • NASDAQ
add
Twist Bioscience Corp
Previous close
$30.10
Day range
$29.67 - $31.03
Year range
$28.46 - $60.90
Market cap
1.85B USD
Avg Volume
1.34M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 92.79M | 23.23% |
Operating expense | 87.59M | 9.80% |
Net income | -39.33M | 13.55% |
Net profit margin | -42.38 | 29.85% |
Earnings per share | -0.66 | 16.46% |
EBITDA | -35.16M | 13.38% |
Effective tax rate | -0.45% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 257.15M | -12.34% |
Total assets | 595.62M | -15.26% |
Total liabilities | 155.51M | 8.96% |
Total equity | 440.11M | — |
Shares outstanding | 59.92M | — |
Price to book | 4.10 | — |
Return on assets | -17.26% | — |
Return on capital | -19.62% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -39.33M | 13.55% |
Cash from operations | -12.99M | 33.14% |
Cash from investing | -1.43M | 72.79% |
Cash from financing | 3.20M | 74.84% |
Net change in cash | -11.11M | 51.48% |
Free cash flow | -5.15M | 14.52% |
About
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Founded
2013
Website
Employees
923
